Search Results for: Clinical Roundup
-
Cerep and PerkinElmer Expand Assay Offering
According to Chief Scientific Officer Marina Guillet, the company specializes in the use of blood tests on kidney transplant patients with signs of chronic humoral rejection and it aims to develop the KRej-X signature as a diagnostic tool in a prospective clinical trial...TcLand Expression, which was founded in 2002 and is based in Nantes, in western France, completed a series A funding round in December 2007 in which it raised €8.2 million from an international group of institutional andBy James Etheridge | BioWorld International | Wednesday, May 6, 2009 -
SpePharm Seeking €35M from BioAlliance Pharma
The company has initiated seven clinical trials of IMP321 over the last four years, and in January reported positive interim results from an ongoing Phase I/II trial in metastatic breast carcinoma...Our positive results in chemo-immunotherapy have encouraged us to engage in discussions with potential partners over Immutep's plans for IMP321," he said.By James Etheridge | BioWorld International | Wednesday, April 22, 2009 -
Biocortech Initiates Trial of Depression Blood Test
BioWorld International Correspondent PARIS - Biocortech has been given the go-ahead by the Comité de Protection des Personnes (CPP), the ethical research committee that has to approve all clinical trials in France, to conduct a proof-of-concept clinical trial to validate a biological test for depression...We are very pleased to see Biocortech's test entering clinical development," said the company's CEO, Dinah Weissmann...This is a major step toward starting to assess the full clinical andBy James Etheridge | BioWorld International | Wednesday, April 15, 2009 -
TcLand, Genedata Collaborate on Autoimmune Biomarkers
TcLand Expression, which raised €8.2 million (US$10.87 million) in a series A funding round in December 2007, also provides immuno-profiling and immunological testing services for biopharmaceutical companies conducting clinical trials in oncology, autoimmune diseases, vaccination and transplantation...Three new companies moved into the campus in 2008, increasing the total number of people employed there to 550.By James Etheridge | BioWorld International | Wednesday, April 1, 2009 -
BioVex Raises $40M to Fund Melanoma Vaccine Study
BioVex said that given the clinical data generated to date, coupled with the mild side effects, OncoVex GM-CSF has the potential to become a leading treatment for many solid tumors...The funds will be used to expand the company's clinical trial programs focusing on bone and cartilage regenerative products for spinal vertebral disc disease...The placement of 15.02 million shares was oversubscribed and was made at a 10 percent discount to the closing price of the company's shares on March 25. #kicker123By Nuala Moran | BioWorld International | Wednesday, April 1, 2009 -
Trophos Extends Partnership with AFM for Olesoxime
Trophos is engaged in a protocol assistance procedure with the EMEA to finalize the design of the clinical efficacy study and to determine the regulatory requirements for obtaining marketing approval for olesoxime as a treatment for SMA...According to the CEO of NicOx, Michele Garufi, taking NCX 6560 into clinical development reflects the company's determination to "expand our drug discovery projects in the cardiometabolic area, where nitric oxide plays a fundamental physiological role...Coreg CRBy James Etheridge | BioWorld International | Wednesday, March 25, 2009 -
Fovea, Dyax Sign Agreement for Ophthalmic Indications
Under the collaboration agreement between the two companies, Novo Nordisk, of Copenhagen, now has full responsibility for preclinical and clinical development for this program, as well as for filing any possible drug candidates that result from it for regulatory approval...To date, Novo Nordisk has taken three monoclonal antibodies into regulatory preclinical development: IPH 2101, now in clinical trials in cancer, and IPH 2201 and IPH 2301, which are in preclinical development in inflammation...TheBy James Etheridge | BioWorld International | Wednesday, February 18, 2009 -
European Farmers Seek to Choose GM Crops
He is currently head of division for European Union cooperation/microbiology at the Paul-Ehrlich-Institut, in Langen, Germany, and an expert in quality and safety of biological medicines, clinical trials and risk mitigation strategies for first-in-man clinical trials, and nonclinical development of biotechnology-derived medicines...She is responsible for marketing authorizations of biological medicinal products at the National Agency for Medicines in Finland, and associate professor in biochemistryBy Peter O'Donnell | BioWorld International | Wednesday, February 18, 2009 -
DBV Technologies Raises €6M in Series B Financing
Innate, Vivalis Collaborate in Monoclonal Antibodies Innate Pharma SA and Vivalis signed a joint collaboration and commercial license agreement covering the use of the Vivalis EB66 cell line for developing an industrial process to manufacture clinical batches of IPH 4101, a novel cytotoxic monoclonal antibody developed by Innate Pharma for the treatment of rare cutaneous lymphomas such as Sezary syndrome and transformed mycosis fungoides...The French Innovation Promotion Agency, OSEO, has advancedBy James Etheridge | BioWorld International | Wednesday, January 28, 2009 -
ExonHit and Alergan Extend Drug Discovery Collaboration
The most advanced compound to have emerged from the collaboration between the two companies so far is EHT/AGN 0001, which is nearing the end of a Phase I clinical trial in pain indications...The two companies earlier halted clinical development of LFA-1 for the treatment of systemic immuno-inflammatory diseases after hepatotoxic side-effects were observed following oral administration...We are confident that this project has a real potential for success, firstly because the compound has already showedBy James Etheridge | BioWorld International | Wednesday, January 14, 2009 -
Cellectis Terminates genOway's Homologous Recombination Deal
The interim results showed a clinical response rate of 50 percent compared to 25 percent with paclitaxel alone, as well as a robust immune response in clinically responsive patients...for the advanced development stages of IMP321, as we continue to collect data from this study at the highest dose," he said.By James Etheridge | BioWorld International | Wednesday, January 7, 2009 -
Hybrigenics Slashes Exercise Price for Existing Warrants
The company also pointed out that the change in expiry date fitted in with its decision to speed up the clinical development of inecalcitol on the strength of the encouraging results obtained from the ongoing Phase IIa trial in the indication of hormone-refractory prostate cancer, which is running ahead of schedule...Clinical trial results to date have demonstrated that it has lower toxicity than calcitriol, the natural active metabolite of vitamin D3, leading Hybrigenics to believe thatBy James Etheridge | BioWorld International | Wednesday, December 3, 2008 -
NicOx Gets Positive Results from Final Naproxcinod Trial
In light of these promising clinical results," said Transgene's CEO, Philippe Archinard, "our product development strategy for TG1042 has evolved to a more ambitious one...As a consequence, we are halting sole development of TG1042 and are seeking a pharmaceutical partner to undertake clinical development in a number of onco-dermatology indications...Today, we are convinced that a partnering strategy will fully optimize our adenovirus franchise, thereby creating more value for the company." #kicker123By Staff Reports | BioWorld International | Wednesday, November 26, 2008 -
F2G Snares £6.3M to Boost Fungal-Fighting Compound
There is significant clinical need for a new systemic agent, and FG3622 has the potential to...Jean-Francois Labbé, SpePharm CEO, said the transactions will help SpePharm build up its sales and marketing force, launch and promote its current products and acquire the rights to additional products.By Nuala Moran | BioWorld International | Wednesday, August 27, 2008 -
Financings Roundup
It will use the money for general operations and for a Phase I clinical trial for its lead oncology product candidate, CLR1404, which is planned to start this summer...The company said it will use the money to complete development of its instrument system, reagent kits for disease-specific clinical research, future diagnostic tests and to support research and development effortsBioWorld International | Wednesday, January 9, 2008 -
EuropaBio Takes Its Message To The Top
The EU currently is implementing a midterm review of its 10-year strategy for life sciences and biotechnology, and industry leaders are seizing the opportunity to drive home the need for a coherent policy across Europe, on everything from clinical trials to the development of a patient-centered public health care system...However, as in the past, the risk is that products that obtain authorization through the default procedure subsequently encounter problems in accessing the market of the countriesBy Peter O'Donnell | BioWorld International | Wednesday, October 17, 2007 -
ASCO Roundup
Following are results of data recently released at the American Society of Clinical Oncology annual meeting in Chicago...Separately, the company's partner Keryx Biopharmaceuticals Inc., of New York, presented Phase I and II results showing that perifosine generated an overall clinical benefit rate of 52 percent, which compares favorably with the activity of mTOR inhibitors, in treating advanced sarcoma...another showed Tykerb has clinical activity in heavily pretreated patients with CNS metastasesBioWorld International | Wednesday, June 6, 2007 -
Alexion Product Benefits From EU's New Fast-Track System
Evidence of clinical benefit of Soliris is limited to patients with a history of transfusions, but the agency said that it considers, on the basis of quality, safety and efficacy data, there is a favorable benefit to risk balance...We need to reverse the budget-driven, cost-containment paradigm of the current healthcare systems in Europe and put at the center of modern policy-making the ultimate consumer of health care: the patient."By Peter O'Donnell | BioWorld International | Wednesday, May 9, 2007 -
AACR Roundup
A prospective clinical study that will include 1,875 individuals began in September, with collaborator bioMerieux, of ParisBioWorld International | Wednesday, April 25, 2007 -
Biotech Innovators Asking For Tighter Biosimilar Naming Rules
In addition, the nature of biosimilar medicines - which are categorized as "similar, but not identical" - means that substitution for the innovator product could have clinical consequences in which patients respond differently to the two products...Eichler, who will take up his post in February 2007, is professor of clinical pharmacology at the Medical University of Vienna, and a member of the Scientific Advice Working Party of the agency's committee on human medicines.By Peter O'Donnell | BioWorld International | Wednesday, November 22, 2006
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.